Research
Hormonal
Tirzepatide treatment was associated with lower hazards of all-cause mortality compared to GLP-1 RA (adjusted hazard ratio [AHR], 0.58; 95% CI, 0.45-0.75).
Practitioners may consider tirzepatide as a safer option for reducing mortality risk in patients with type 2 diabetes.
StrongSupportsmedium confidence
Tirzepatide treatment was associated with lower hazards of all-cause mortality (adjusted hazard ratio [AHR], 0.58; 95% CI, 0.45-0.75).
Why this rating
Based on a large retrospective cohort study design.
Source
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes
Min‐Hsiang Chuang et al. · JAMA Network Open · 2024
cohort · n=140308Cited 106×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →